SANUWAVE, Inc. dermaPACE Technology Shown Superior to Hyperbaric Oxygen Therapy in Increasing Angiogenic and Tissue Regenerative Molecular Changes in Diabetic Foot Ulcers

ALPHARETTA, Ga.--(BUSINESS WIRE)--SANUWAVE Health, Inc. (OTCBB: SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced the publication of research that investigated the molecular changes of dermaPACE® extracorporeal shock wave technology (ESWT) compared with hyperbaric oxygen therapy (HBOT) in diabetic foot ulcers. The study, titled “Molecular Changes in Diabetic Foot Ulcers,” by Ching-Jen Wang, M.D. of the Department of Orthopedic Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine in Kaohsiung, Taiwan, appeared in the online edition of the European peer-reviewed journal Diabetes Research and Clinical Practice as an ePublication ahead of print.